Table 3.
Antibody | Aβ chains | Binding energy | Total residue number | Normalized binding energy |
---|---|---|---|---|
kcal/mol | kcal/mol/residue | |||
Solanezumab | 1-mer | −74.3 ± 3.7 | 451 | −0.165 |
5-mer | −3.9 ± 4.5 | 594 | −0.007 | |
16-mer | −41.2 ± 6.3 | 946 | −0.044 | |
Crenezumab | 1-mer | −66.0 ± 3.7 | 451 | −0.146 |
5-mer | −39.8 ± 4.4 | 594 | −0.067 | |
16-mer | −195.8 ± 6.3 | 946 | −0.207 | |
Crenezumab chimera | 1-mer | −17.8 ± 3.7 | 451 | −0.039 |
5-mer | −6.4 ± 4.5 | 594 | −0.011 | |
16-mer | −85.2 ± 6.0 | 946 | −0.090 |